advanced renal cell carcinoma

Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Motley Fool
Sat, 01/23/21 - 11:35 pm
Exelixis
FDA
Cabometyx
Cometriq
advanced renal cell carcinoma
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Tue, 11/10/20 - 11:10 am
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Pharmaforum
Wed, 05/15/19 - 10:35 am
Merck KGaA
Pfizer
Bavencio
FDA
Inlyta
advanced renal cell carcinoma
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Pharmaceutical Business Review
Thu, 05/2/19 - 11:20 am
Exelixis
clinical trials
cabozantinib
Cabometyx
advanced renal cell carcinoma
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Mon, 04/22/19 - 11:11 am
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Aveo stock plunges after delay in FDA approval submission for cancer drug
Bizjournals
Fri, 02/1/19 - 12:16 am
Aveo Oncology
kidney cancer
FDA
tivozanib
advanced renal cell carcinoma
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
CP Wire
Fri, 09/7/18 - 11:05 am
Exelixis
Cabometyx
advanced renal cell carcinoma
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
Fri, 09/7/18 - 09:44 am
Exelixis
Cabometyx
advanced renal cell carcinoma
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Thu, 05/17/18 - 09:42 am
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Sun, 06/5/16 - 11:59 am
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Eisai's kidney drug wins expanded indication in the U.S.
BioPharma Dive
Tue, 05/17/16 - 09:35 am
Eisai
advanced renal cell carcinoma
kidney cancer
Lenvima
RCC